跳至主要内容
临床试验/NCT00451399
NCT00451399已完成4 期

Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison

Central South University1 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2004年10月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
128
试验地点
1
主要终点
body weight, body mass index, waist circumference, fasting glucose, fasting insulin, insulin resistance index

研究概览

简要总结

Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies. We conducted a randomized, placebo-controlled study to test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain.

详细描述

The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention.128 patients were randomized to one of four 12-week individual treatments: metformin (750mg/day), placebo, lifestyle intervention plus metformin (750mg/day) or lifestyle intervention plus placebo. Medications were provided in double-blind fashion.The assessments include body weight, body mass index, waist circumference, fasting glucose, fasting insulin and insulin resistance index.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia
  • Participants were required to get weight gain more than 10% of their predrug body weight during less than 12 months of treatment with a targeted antipsychotic agent- clozapine, olanzapine, risperidone or sulpiride.
  • The duration of illness for all participants was less than 12 months.
  • Participants could be taking only one antipsychotic, whose dose had not changed by changed by more than 25% over the past 3 months.
  • All patients were stable outpatient.
  • The total score of Positive and Negative Syndrome Scale (PANSS) for all patients could be ≤
  • All participants were ensured that they could be carefully taken care of by one of their parents or guardians during the trial.

排除标准

  • Participants were excluded from the study if they had evidence of liver or renal diseases, pregnant or lactating women, cardiovascular diseases, hypertension or diabetes mellitus, specific systemic diseases, or conditions that limited their ability to perform the lifestyle modifications, such as arthritis, pulmonary diseases, neurological or dietary restrictions.

结局指标

主要结局

body weight, body mass index, waist circumference, fasting glucose, fasting insulin, insulin resistance index

次要结局

未报告次要终点

研究者

发起方
Central South University
申办方类型
Other

研究点 (1)

Loading locations...

相似试验